Randomised controlled trial of population screening for atrial fibrillation in people aged 70 years and over to reduce stroke: protocol for the SAFER trial.

11 Indeed, the STROKESTOP screening trial reported a marginally significant reduction in a revised composite primary endpoint of stroke, systemic embolism, bleeding leading to hospitalisation and all-cause death. 9 Another potential benefit of screening for AF is to reduce risk of cognitive decline and vascular dementia. 14–17 In terms of harm, the major concern is risk of bleeding as a result of anticoagulation of people identified as being in AF.

also in 26,082 other papers